证券记录 · 已归档季度
TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
21被追踪持有人
-1Δ持有人
89.79M持有股份
$1.98B报告持仓市值
+0新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 -4.5% ·
股份流向 -8.7% ·
净新建仓位 -4.8%
— 公式
广泛派发 — 持股数量下降且持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q4 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 149 | +7 | 367.15M | $12.41B | +9 | −3 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | — | — |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | — | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | — | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | — |
| Q2 2024 | 19 | — | 61.88M | $1.01B | — | — |
持有人 · Q4 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (被动) | 19.41M | — | $427.89M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (被动) | 9.28M | +5.6% | $203.64M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Duquesne Family Office ✦ | 9.00M | +530.1% | $198.30M | 5.6% | ▲ Add | 2 | SEC ↗ |
| 4 | Glenview Capital ✦ | 8.46M | 0.0% | $186.38M | 4.7% | Held | 3 | SEC ↗ |
| 5 | Arrowstreet Capital ✦ | 6.99M | -53.1% | $154.07M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 6.98M | -14.0% | $153.76M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 7 | Millennium Management ✦ | 6.54M | -44.6% | $144.19M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 8 | Viking Global Investors ✦ | 6.50M | -14.1% | $143.34M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 9 | Marshall Wace ✦ | 5.16M | +87.8% | $113.63M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 2.51M | -31.3% | $55.30M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 2.39M | -31.2% | $52.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 2.05M | +148.3% | $45.17M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 13 | Norges Bank ✦ (被动) | 1.75M | +15.4% | $38.55M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 1.20M | -66.9% | $26.45M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 686.46K | -4.0% | $15.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Greenlight Capital (DME Capital) ✦ | 468.55K | +44.2% | $10.33M | 0.5% | ▲ Add | 3 | SEC ↗ ×2 |
| 17 | Wellington Management ✦ | 185.91K | +2.1% | $4.10M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 18 | GAMCO Investors ✦ | 105.60K | -18.6% | $2.33M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | ARK Investment Management ✦ | 100.44K | -18.9% | $2.21M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 19.22K | +9.4% | $423,675 | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 21 | Bridgewater Associates ✦ | 9.39K | -59.5% | $207,022 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Point72 Asset Management | $9.33M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 646 持有人, 666.61M 股份, $16.70B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 18
Savage Brian
Officer · 2.52K 股 · $98,841
Sep 18
MIGNONE ROBERTO
Director · 367.60K 股 · $14.36M
Sep 18
Savage Brian
Officer · 4.50K 股 · $174,221
Sep 18
Savage Brian
Officer · 314 股 · $12,153
Aug 21
Weiss Amir
Officer · 2.50K 股 · $94,077
Aug 21
Satchi-Fainaro Ronit
Director · 415 股 · $15,459
Aug 21
Weiss Amir
Officer · 6.95K 股 · $261,224
Aug 17
Lippman Evan
Officer · 18.60K 股 · $680,291
Aug 05
Zaks Tal Zvi
Director · 17 股 · $593
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q4 2024 ·
方法论 ·
通过API获取此数据